Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

RMD open

Showing results (491-500 of 1,920) with videos related to

Pageof 192
Sort By:
RMD Open|March 20, 2019
Evaluation of the efficacy and safety of sarilumab combination therapy in patients with rheumatoid arthritis with inadequate response to conventional disease-modifying antirheumatic drugs or tumour necrosis factor α inhibitors: systematic literature review and network meta-analysesErnest Choy, Nick Freemantle, Clare Proudfoot, et al.
RMD Open|March 20, 2019
Correction: Ixekizumab is efficacious when used alone or when added to conventional synthetic disease-modifying antirheumatic drugs (cDMARDs) in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor inhibitors
RMD Open|February 23, 2019
Short-term risk of major adverse cardiovascular events or congestive heart failure in patients with psoriatic arthritis or psoriasis initiating a biological therapy: a meta-analysis of randomised controlled trialsBénédicte Champs, Yannick Degboé, Thomas Barnetche, et al.
RMD Open|August 16, 2019
Comparative effect of tumour necrosis factor inhibitors versus other biological agents on cardiovascular risk-associated biomarkers in patients with rheumatoid arthritisAlexandre Virone, Jean-Philippe Bastard, Soraya Fellahi, et al.
RMD Open|August 16, 2019
Impact of the combined presence of erosions and ACPA on rheumatoid arthritis disease activity over time: results from the METEOR registrySytske Anne Bergstra, Maura C Couto, Nimmisha Govind, et al.
RMD Open|February 2, 2021
Long-term safety and efficacy of sirukumab for patients with rheumatoid arthritis who previously received sirukumab in randomised controlled trials (SIRROUND-LTE)Daniel Aletaha, Clifton O Bingham, George Athanasios Karpouzas, et al.
RMD Open|January 18, 2021
Biological agents for rheumatic diseases in the outbreak of COVID-19: friend or foe?Cristiana Sieiro Santos, Xenia Cásas Férnandez, Clara Moriano Morales, et al.
RMD Open|January 28, 2021
Effect of significant weight loss on disease activity: reason to implement this non-pharmaceutical intervention in daily clinical practiceJulia M Weijers, Wieland D Müskens, Piet L C M van Riel
RMD Open|January 20, 2021
Inflammaging as a link between autoimmunity and cardiovascular disease: the case of rheumatoid arthritisPedro Santos-Moreno, Gabriel Burgos-Angulo, Maria Alejandra Martinez-Ceballos, et al.
RMD Open|January 6, 2022
Immunogenicity of BNT162b2 mRNA SARS-CoV-2 vaccine in patients with psoriatic arthritis on TNF inhibitorsVincenzo Venerito, Pasquale Stefanizzi, Marco Fornaro, et al.
Pageof 192

Showing results (491-500 of 1,920) with videos related to

Sort By:
Pageof 192
RMD Open|March 20, 2019
Evaluation of the efficacy and safety of sarilumab combination therapy in patients with rheumatoid arthritis with inadequate response to conventional disease-modifying antirheumatic drugs or tumour necrosis factor α inhibitors: systematic literature review and network meta-analysesErnest Choy, Nick Freemantle, Clare Proudfoot, et al.
RMD Open|March 20, 2019
Correction: Ixekizumab is efficacious when used alone or when added to conventional synthetic disease-modifying antirheumatic drugs (cDMARDs) in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor inhibitors
RMD Open|February 23, 2019
Short-term risk of major adverse cardiovascular events or congestive heart failure in patients with psoriatic arthritis or psoriasis initiating a biological therapy: a meta-analysis of randomised controlled trialsBénédicte Champs, Yannick Degboé, Thomas Barnetche, et al.
RMD Open|August 16, 2019
Comparative effect of tumour necrosis factor inhibitors versus other biological agents on cardiovascular risk-associated biomarkers in patients with rheumatoid arthritisAlexandre Virone, Jean-Philippe Bastard, Soraya Fellahi, et al.
RMD Open|August 16, 2019
Impact of the combined presence of erosions and ACPA on rheumatoid arthritis disease activity over time: results from the METEOR registrySytske Anne Bergstra, Maura C Couto, Nimmisha Govind, et al.
RMD Open|February 2, 2021
Long-term safety and efficacy of sirukumab for patients with rheumatoid arthritis who previously received sirukumab in randomised controlled trials (SIRROUND-LTE)Daniel Aletaha, Clifton O Bingham, George Athanasios Karpouzas, et al.
RMD Open|January 18, 2021
Biological agents for rheumatic diseases in the outbreak of COVID-19: friend or foe?Cristiana Sieiro Santos, Xenia Cásas Férnandez, Clara Moriano Morales, et al.
RMD Open|January 28, 2021
Effect of significant weight loss on disease activity: reason to implement this non-pharmaceutical intervention in daily clinical practiceJulia M Weijers, Wieland D Müskens, Piet L C M van Riel
RMD Open|January 20, 2021
Inflammaging as a link between autoimmunity and cardiovascular disease: the case of rheumatoid arthritisPedro Santos-Moreno, Gabriel Burgos-Angulo, Maria Alejandra Martinez-Ceballos, et al.
RMD Open|January 6, 2022
Immunogenicity of BNT162b2 mRNA SARS-CoV-2 vaccine in patients with psoriatic arthritis on TNF inhibitorsVincenzo Venerito, Pasquale Stefanizzi, Marco Fornaro, et al.
Pageof 192